SCHEMBL6443012

SCHEMBL6443012

N#CCC(=O)c1ccc(C#N)o1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 2/20 0.43
CHRNB4 P30926 2/20 0.43
CHRNA3 P32297 2/20 0.43
CHRNA4 P43681 2/20 0.43
KCNH2 Q12809 4/20 0.41
FAAH O00519 4/20 0.38
CES1 P23141 4/20 0.38
NCEH1 Q6PIU2 3/20 0.38
CSF1R P07333 7/20 0.37
MCL1 Q07820 1/20 0.36
ALDH1A1 P00352 1/20 0.34
POLB P06746 1/20 0.34
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34
RECQL P46063 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9371766 0.81 GSK3B (0.47) CHRNB2CHRNB4CHRNA3CHRNA4FAAH
SCHEMBL1426436 0.79 ALDH1A1 (0.49) KCNH2ALDH1A1MEN1MAPTKMT2A
SCHEMBL6440784 0.79 KCNH2 (0.46) KCNH2ALDH1A1POLBMAPT
SCHEMBL6867799 0.78 TDP1 (0.56) KCNH2MCL1ALDH1A1POLBKDM4E
SCHEMBL27591963 0.77 KCNH2 (0.41) KCNH2MCL1ALDH1A1POLBKDM4E
SCHEMBL2910035 0.75 CHRNA4 (0.51) CHRNB2CHRNB4CHRNA3CHRNA4FAAH
SCHEMBL15128974 0.74 FFAR1 (0.45) CHRNB2CHRNB4CHRNA3CHRNA4KCNH2
SCHEMBL2915232 0.74 CHRNA4 (0.47) CHRNB2CHRNB4CHRNA3CHRNA4FAAH
SCHEMBL16131795 0.74 CHRNB2 (0.46) CHRNB2CHRNB4CHRNA3CHRNA4FAAH
SCHEMBL9373067 0.74 CHRNB2 (0.46) CHRNB2CHRNB4CHRNA3CHRNA4CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 CHRNB2 29/4885CHRNB4 27/4885CHRNA3 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.